Q3 EPS Forecast for Verve Therapeutics Lifted by Analyst

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at William Blair raised their Q3 2025 earnings estimates for Verve Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.73) for the quarter, up from their prior forecast of ($0.75). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. William Blair also issued estimates for Verve Therapeutics' Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.52) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.97) EPS and FY2027 earnings at ($3.36) EPS.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million.

A number of other brokerages have also issued reports on VERV. HC Wainwright boosted their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Guggenheim boosted their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Canaccord Genuity Group boosted their target price on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Finally, Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $25.75.

Verve Therapeutics Trading Up 7.2%

Shares of VERV stock opened at $4.63 on Monday. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $9.31. The firm's fifty day simple moving average is $4.78 and its 200 day simple moving average is $5.86. The firm has a market capitalization of $412.73 million, a P/E ratio of -1.88 and a beta of 1.82.

Institutional Investors Weigh In On Verve Therapeutics

A number of institutional investors have recently bought and sold shares of VERV. BVF Inc. IL boosted its stake in Verve Therapeutics by 962.2% during the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock worth $38,939,000 after buying an additional 6,254,050 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of Verve Therapeutics in the 1st quarter valued at $12,648,000. Point72 Asset Management L.P. acquired a new stake in shares of Verve Therapeutics in the 4th quarter valued at $7,863,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of Verve Therapeutics by 57.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock valued at $21,372,000 after purchasing an additional 1,382,176 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Verve Therapeutics in the 1st quarter valued at $6,054,000. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.